Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

New technology promises tests for diseases such as cancer in 15 minutes

Scientists at Leeds University in the UK say soon, testing for diseases such as cancer and multiple sclerosis, could take as little as 15 minutes and could be as simple as using a pregnancy testing kit.

1 Oct 2008

Multiple sclerosis patients have higher spinal fluid levels of suspicious immune molecule

A protein that helps keep immune cells quiet is more abundant in the spinal fluid of patients with multiple sclerosis (MS), further boosting suspicion that the protein, TREM-2, may be an important contributor to the disease.

29 Sep 2008

Pain is not a symptom of arthritis, pain causes arthritis

Pain is more than a symptom of osteoarthritis, it is an inherent and damaging part of the disease itself, according to a study published today in journal Arthritis and Rheumatism.

29 Sep 2008

GlaxoSmithKline and Cellzome announce major strategic alliance

Cellzome Inc. and GlaxoSmithKline have announced the signing of a worldwide strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases.

10 Sep 2008

FDA 'fast track' granted to BioMS Medical for lead drug, dirucotide for the treatment of multiple sclerosis

BioMS Medical Corp has announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.

4 Sep 2008

MorphoSys announces publication of first MOR103 data

MorphoSys AG announced today the publication of a first data package for its most advanced proprietary drug development program MOR103, a fully human HuCAL antibody directed against GM-CSF, in the journal "Molecular Immunology".

2 Sep 2008

Genmab announces four studies of ofatumumab in chronic lymphocytic leukemia

Genmab A/S announced today plans to begin four studies of ofatumumab in chronic lymphocytic leukemia (CLL) and follicular non-Hodgkin's lymphoma (NHL) this year.

25 Aug 2008

In-depth review of current research on the health effects of vitamin D

Despite considerable progress in research to understand the health effects of vitamin D, experts convened by the NIH to review the available data found major gaps in the evidence. The data are strongest in the area of bone health among elderly men and post-menopausal women, suggesting that increased vitamin D intake can improve bone health and prevent falls. For other age groups and health issues, though, it is too early to say conclusively whether more vitamin D might be beneficial.

12 Aug 2008

Cannabinoid cell surface receptor plays a tumor-suppressing role in human colorectal cancer

CB1 is well-established for relieving pain and nausea, elevating mood and stimulating appetite by serving as a docking station for the cannabinoid group of signaling molecules. It now may serve as a new path for cancer prevention or treatment.

3 Aug 2008

Luna awarded NIH grant for fullerene-based nanomedicines as allergy treatments

Luna Innovations Incorporated has announced the award of a $1.6 million Research Project Grant (R01) from the National Institutes of Health (NIH) to investigate the use of fullerene-based nanomedicines as a pathway to treat allergies and other inflammatory diseases.

22 Jul 2008

CUPID cannabinoid MS study reaches milestone

The CUPID (Cannabinoid Use in Progressive Inflammatory brain Disease) study at the Peninsula Medical School in Plymouth has reached an important milestone with the news that the full cohort of 493 people with multiple sclerosis (MS) has been recruited to the study.

21 Jul 2008

New ways of exploiting medicinal uses of cannabis

Research exploring new ways of exploiting the full medicinal uses of cannabis while avoiding unwanted side-effects will be presented to pharmacologists Tuesday, 15 July by leading scientists attending the Federation of European Pharmacological Societies Congress, EPHAR 2008.

From The University of Manchester 15 Jul 2008

New center for protein therapeutics formed by UB pharmaceutical scientists

Pharmaceutical researchers at the University at Buffalo have joined forces with scientists from several of the world's largest pharmaceutical companies to tackle fundamental research questions that need to be answered to advance development of promising protein-based drugs.

15 Jul 2008

Statins have unexpected effect on pool of powerful brain cells

Cholesterol-lowering drugs known as statins have a profound effect on an elite group of cells important to brain health as we age, scientists at the University of Rochester Medical Center have found. The new findings shed light on a long-debated potential role for statins in the area of dementia.

3 Jul 2008

New insight into role of statins in dementia

3 Jul 2008

Caffeine could help prevent multiple sclerosis

A new study is suggesting that having several cups of coffee a day could halt the development of multiple sclerosis (MS).

2 Jul 2008

New Australian health programmes provide health checks for children and teen dental care

Three new health programmes for children and teenagers have been announced by the Australian Federal Government which include a $150 voucher for teenage dental care, free health checks for children starting school and a guide to kids' health for parents.

2 Jul 2008

Oral cannabis ineffective in treating acute pain

A study published in the July issue of the Journal Anesthesiology discovered that oral cannabis (a form of medical marijuana) not only failed to alleviate certain types of pain in human volunteers but, surprisingly, it instead caused increased sensitivity to some forms of pain.

24 Jun 2008

Discovery of possible new way to block inflammation in autoimmune disease

Researchers from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health (NIH), have identified a promising new target for autoimmune disease treatment - a cell-surface receptor called DR3.

23 Jun 2008

Bionomics and Merck Serono to collaborate to discover and develop novel, oral treatment for MS

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that a Development and Licensing Agreement with Bionomics was signed, under which Merck Serono would develop new treatments for multiple sclerosis (MS) and other autoimmune conditions based on compounds from Bionomics Kv1.3 program.

19 Jun 2008